vs

Side-by-side financial comparison of CPS TECHNOLOGIES CORP (CPSH) and IRIDEX CORP (IRIX). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $8.2M, roughly 1.8× CPS TECHNOLOGIES CORP). On growth, CPS TECHNOLOGIES CORP posted the faster year-over-year revenue change (38.3% vs -69.7%). Over the past eight quarters, CPS TECHNOLOGIES CORP's revenue compounded faster (17.8% CAGR vs 11.9%).

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

CPSH vs IRIX — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.8× larger
IRIX
$14.7M
$8.2M
CPSH
Growing faster (revenue YoY)
CPSH
CPSH
+108.1% gap
CPSH
38.3%
-69.7%
IRIX
Faster 2-yr revenue CAGR
CPSH
CPSH
Annualised
CPSH
17.8%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPSH
CPSH
IRIX
IRIX
Revenue
$8.2M
$14.7M
Net Profit
$12.6K
Gross Margin
14.9%
37.2%
Operating Margin
-1.2%
Net Margin
0.2%
Revenue YoY
38.3%
-69.7%
Net Profit YoY
101.3%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPSH
CPSH
IRIX
IRIX
Q4 25
$8.2M
$14.7M
Q3 25
$8.8M
$12.5M
Q2 25
$8.1M
$13.6M
Q1 25
$7.5M
$11.9M
Q4 24
$5.9M
$12.7M
Q3 24
$4.2M
$11.6M
Q2 24
$5.0M
$12.6M
Q1 24
$5.9M
$11.8M
Net Profit
CPSH
CPSH
IRIX
IRIX
Q4 25
$12.6K
Q3 25
$208.0K
$-1.6M
Q2 25
$103.8K
$-994.0K
Q1 25
$96.0K
$-1.7M
Q4 24
$-995.2K
$-834.0K
Q3 24
$-1.0M
$-1.9M
Q2 24
$-954.3K
$-2.7M
Q1 24
$-143.2K
$-3.5M
Gross Margin
CPSH
CPSH
IRIX
IRIX
Q4 25
14.9%
37.2%
Q3 25
17.1%
32.1%
Q2 25
16.5%
34.5%
Q1 25
16.4%
42.5%
Q4 24
-4.6%
44.0%
Q3 24
-12.3%
37.3%
Q2 24
-4.6%
40.7%
Q1 24
15.3%
37.9%
Operating Margin
CPSH
CPSH
IRIX
IRIX
Q4 25
-1.2%
Q3 25
3.1%
-11.3%
Q2 25
1.7%
-6.9%
Q1 25
1.7%
-1.7%
Q4 24
-22.2%
-3.9%
Q3 24
-35.0%
-16.1%
Q2 24
-26.1%
-20.9%
Q1 24
-4.4%
-28.0%
Net Margin
CPSH
CPSH
IRIX
IRIX
Q4 25
0.2%
Q3 25
2.4%
-12.6%
Q2 25
1.3%
-7.3%
Q1 25
1.3%
-14.2%
Q4 24
-16.8%
-6.6%
Q3 24
-24.6%
-16.7%
Q2 24
-19.0%
-21.2%
Q1 24
-2.4%
-29.5%
EPS (diluted)
CPSH
CPSH
IRIX
IRIX
Q4 25
$0.00
Q3 25
$0.01
$-0.09
Q2 25
$0.01
$-0.06
Q1 25
$0.01
$-0.10
Q4 24
$-0.07
$-0.05
Q3 24
$-0.07
$-0.12
Q2 24
$-0.07
$-0.16
Q1 24
$-0.01
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPSH
CPSH
IRIX
IRIX
Cash + ST InvestmentsLiquidity on hand
$13.2M
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$24.6M
Total Assets
$29.5M
$29.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPSH
CPSH
IRIX
IRIX
Q4 25
$13.2M
$6.0M
Q3 25
$4.3M
$5.6M
Q2 25
$3.4M
$6.8M
Q1 25
$3.0M
$7.2M
Q4 24
$4.3M
$2.4M
Q3 24
$5.7M
$3.9M
Q2 24
$7.1M
$4.1M
Q1 24
$8.7M
$5.4M
Total Debt
CPSH
CPSH
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.1K
$1.0M
Q3 24
$20.1K
$1.4M
Q2 24
$31.9K
Q1 24
$43.5K
Stockholders' Equity
CPSH
CPSH
IRIX
IRIX
Q4 25
$24.6M
Q3 25
$15.1M
$4.7M
Q2 25
$14.9M
$6.1M
Q1 25
$14.7M
$852.0K
Q4 24
$14.5M
$2.1M
Q3 24
$15.4M
$2.6M
Q2 24
$16.4M
$4.2M
Q1 24
$17.3M
$6.5M
Total Assets
CPSH
CPSH
IRIX
IRIX
Q4 25
$29.5M
$29.2M
Q3 25
$20.4M
$28.4M
Q2 25
$19.4M
$31.6M
Q1 25
$19.2M
$34.2M
Q4 24
$18.9M
$29.1M
Q3 24
$19.2M
$30.2M
Q2 24
$20.1M
$31.2M
Q1 24
$21.2M
$34.1M
Debt / Equity
CPSH
CPSH
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
0.48×
Q3 24
0.00×
0.53×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPSH
CPSH
IRIX
IRIX
Operating Cash FlowLast quarter
$243.6K
Free Cash FlowOCF − Capex
$-487.0K
FCF MarginFCF / Revenue
-5.9%
Capex IntensityCapex / Revenue
8.9%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$-479.6K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPSH
CPSH
IRIX
IRIX
Q4 25
$243.6K
Q3 25
$1.1M
$-1.2M
Q2 25
$649.3K
$-397.0K
Q1 25
$-1.3M
$-1.1M
Q4 24
$-3.5M
$-1.2M
Q3 24
$-1.2M
$-3.1M
Q2 24
$-1.0M
$-1.3M
Q1 24
$128.9K
$-1.6M
Free Cash Flow
CPSH
CPSH
IRIX
IRIX
Q4 25
$-487.0K
Q3 25
$876.8K
$-1.2M
Q2 25
$476.4K
$-410.0K
Q1 25
$-1.3M
$-1.2M
Q4 24
$-4.5M
$-1.2M
Q3 24
$-1.3M
$-3.1M
Q2 24
$-1.6M
Q1 24
$-134.5K
$-1.7M
FCF Margin
CPSH
CPSH
IRIX
IRIX
Q4 25
-5.9%
Q3 25
10.0%
-9.4%
Q2 25
5.9%
-3.0%
Q1 25
-17.9%
-9.8%
Q4 24
-75.3%
-9.8%
Q3 24
-29.8%
-26.5%
Q2 24
-31.8%
Q1 24
-2.3%
-14.0%
Capex Intensity
CPSH
CPSH
IRIX
IRIX
Q4 25
8.9%
Q3 25
2.0%
0.1%
Q2 25
2.1%
0.1%
Q1 25
1.2%
0.1%
Q4 24
16.8%
0.1%
Q3 24
1.9%
0.0%
Q2 24
11.0%
0.0%
Q1 24
4.5%
0.0%
Cash Conversion
CPSH
CPSH
IRIX
IRIX
Q4 25
19.34×
Q3 25
5.05×
Q2 25
6.25×
Q1 25
-13.05×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons